Trial Profile
Pharmacological cardioversion of nifekalant for ventricular fibliration or tachycardia following reperfuion
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Sep 2018
Price :
$35
*
At a glance
- Drugs Nifekalant (Primary)
- Indications Arrhythmias
- Focus Therapeutic Use
- 04 Sep 2018 New trial record